Synlogic, Inc.

SYBX Healthcare Biotechnology

Synlogic, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $8,000.00, down 99.8% from fiscal 2023. In the quarter to June 2026, EPS was flat and free cash flow fell 277.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

1.00 0.08 −7.41%
Market cap
$6.7M
P/E
0.0×
Fwd P/E
−2.8×
Dividend yield
—
F-score
3/9
Altman Z
−35.79
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
9.19 7.08 4.30 2.65
Net Debt/EBITDA
13.03 10.69 10.93 15.73
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.07) (0.05) (0.07) (0.12)
Book value per Share
0.97 1.01 0.96 0.84
Free Cash Flow
(0.92) (0.56) (0.92) (1.44)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates